Investment guidance for the Chinese medical device market

The medical device market is one of the most attractive and profitable areas in the global economy. Since China opened its doors to the world it has attracted increasing amounts of foreign investment. The Chinese medical device market is currently one of the most promising and fastest growing markets, which is the second largest market in the world with 200 billion yuan (RMB) total sales in 2013. This paper illustrates the geographical distribution of the Chinese medical device industry, combined with the location quotient (LQ) assessment, to reveal the medical device industry’s professional level and degree of concentration in each province, providing guidance for investors who are interested in medical device investment in China. The LQ and market share (MS) matrix reveals that the best investment regions in China are: Bohai Economic Rim, Yangtze River Delta and Pearl River Delta Economic Zones

The medical device market and its industrial evolution in China

China has attracted increasing amounts of foreign investment since it opened its doors to the world and whilst many researchers have focused on foreign investment in popular areas, little has been written about medical device market. The medical device market is one of the most profitable areas in the global economy. With the development of China’s economy, the Chinese medical device market is experiencing significant growth, and has become the second largest market in the world. The research in this thesis extracted foreign direct investment theory and summarized the current situation of the global medical device market and the Chinese medical device market. Analysis of the status of the Chinese medical device market from the perspective of the healthcare industry and its important market drivers, reveals that the medical device market has significant growth potential. The research methods such as: regression analysis; location quotient, which revealed the Chinese medical device market status, provides suggestions for investors who are interested in entering the Chinese market. Investors or companies who want to enter the Chinese market need to understand the regulatory environment, comparison of the medical device regulations with the US and EU regulations provide investors with a clear understanding of the Chinese medical device regulatory regime. The research in this thesis contributes to medical device market investment and regional economy in medical device industry, and make a clear statement of the changing medical device regulations in China, which came into force on 2014. The contribution of this thesis, bridges the research gap between investment theory and medical device market development

The Chinese medical device market: market drivers and investment prospects

The economy in China has experienced rapid growth and been remarkably successful ever since the reforming and opening-up policy. Like China’s economy, the Chinese medical device market is developing rapidly; this paper identifies important parameters controlling this market. Regression analysis shows that the number of hospital visits, aging population and the number of hospitals have a positive relationship with medical device revenues. Therefore, they are the main drivers of the Chinese medical device market. Disease profile is another important market driver. Analysis of the main market drivers, illustrates that the Chinese medical device market offers significant investment opportunities

Marketing authorization of medical devices in China

Medical device regulations across the globe have significant variations. The Chinese medical device market, like China’s economy, is developing rapidly. This article reviews the medical device regulations in China and illustrates the major changes that have been recently implemented according to the new medical device regulations that came into force on the 1st June, 2014. Most regulatory research has focused on the US and EU medical device regulations with little written about the Chinese medical device regulations. The purpose of this article is to bridge the research gap and to introduce the Chinese medical devices regulatory environment to investors or companies who are engaged in the medical device market or doing business in China

Antitumor Agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents

A combined approach of validated QSAR modeling and virtual screening was successfully applied to the discovery of novel tylophrine derivatives as anticancer agents. QSAR models have been initially developed for 52 chemically diverse phenanthrine-based tylophrine derivatives (PBTs) with known experimental EC50 using chemical topological descriptors (calculated with the MolConnZ program) and variable selection k nearest neighbor (kNN) method. Several validation protocols have been applied to achieve robust QSAR models. The original dataset was divided into multiple training and test sets, and the models were considered acceptable only if the leave-one-out cross-validated R2 (q2) values were greater than 0.5 for the training sets and the correlation coefficient R2 values were greater than 0.6 for the test sets. Furthermore, the q2 values for the actual dataset were shown to be significantly higher than those obtained for the same dataset with randomized target properties (Y-randomization test), indicating that models were statistically significant. Ten best models were then employed to mine a commercially available ChemDiv Database (ca. 500K compounds) resulting in 34 consensus hits with moderate to high predicted activities. Ten structurally diverse hits were experimentally tested and eight were confirmed active with the highest experimental EC50 of 1.8µM implying an exceptionally high hit rate (80%). The same ten models were further applied to predict EC50 for four new PBTs, and the correlation coefficient (R2) between the experimental and predicted EC50 for these compounds plus eight active consensus hits was shown to be as high as 0.57. Our studies suggest that the approach combining validated QSAR modeling and virtual screening could be successfully used as a general tool for the discovery of novel biologically active compounds

Neuroimaging markers for studying Gulf-War illness: single-subject level analytical method based on machine learning

Gulf War illness (GWI) refers to the multitude of chronic health symptoms, spanning from fatigue, musculoskeletal pain, and neurological complaints to respiratory, gastrointestinal, and dermatologic symptoms experienced by about 250,000 GW veterans who served in the 1991 Gulf War (GW). Longitudinal studies showed that the severity of these symptoms often remain unchanged even years after the GW, and these veterans with GWI continue to have poorer general health and increased chronic medical conditions than their non-deployed counterparts. For better management and treatment of this condition, there is an urgent need for developing objective biomarkers that can help with simple and accurate diagnosis of GWI. In this study, we applied multiple neuroimaging techniques, including T1-weighted magnetic resonance imaging (T1W-MRI), diffusion tensor imaging (DTI), and novel neurite density imaging (NDI) to perform both a group-level statistical comparison and a single-subject level machine learning (ML) analysis to identify diagnostic imaging features of GWI. Our results supported NDI as the most sensitive in defining GWI characteristics. In particular, our classifier trained with white matter NDI features achieved an accuracy of 90% and F-score of 0.941 for classifying GWI cases from controls after the cross-validation. These results are consistent with our previous study which suggests that NDI measures are sensitive to the microstructural and macrostructural changes in the brain of veterans with GWI, which can be valuable for designing better diagnosis method and treatment efficacy studies.W81XWH-17-1-0440 - a department of Defense CDMRP new investigator awardPublished versio